Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
Author
Source
Chemotherapy Research and Practice
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-09-25
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2) protein, mainly as a result of gene amplification.
The receptor tyrosine kinase is believed to play a critical role in the pathogenesis and further proliferation of these tumors.
The application of trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, to HER2-positive metastatic breast cancer has significantly improved treatment outcomes.
Following this success, several phase III trials have evaluated the role of trastuzumab in the adjuvant setting, with the result that trastuzumab use is now the standard of care for most HER2-positive early breast cancer patients.
In this paper, we review these pivotal phase III trials.
We also discuss unresolved issues in adjuvant treatment with trastuzumab, including target patient population, sequential or concurrent use with chemotherapy or radiation, treatment duration, cardiotoxicity, and the possibility of eliminating chemotherapy.
Following confirmation of its ability to partially overcome trastuzumab resistance, we also discuss the role of lapatinib in adjuvant use.
American Psychological Association (APA)
Mukohara, Toru. 2011. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice،Vol. 2011, no. 2011, pp.1-12.
https://search.emarefa.net/detail/BIM-494092
Modern Language Association (MLA)
Mukohara, Toru. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice No. 2011 (2011), pp.1-12.
https://search.emarefa.net/detail/BIM-494092
American Medical Association (AMA)
Mukohara, Toru. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice. 2011. Vol. 2011, no. 2011, pp.1-12.
https://search.emarefa.net/detail/BIM-494092
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-494092